← Back to headlines
Insmed Discontinues Skin Disorder Drug Candidate After Trial Setback
Insmed announced it is discontinuing the development of its skin disorder drug candidate, brensocatib, after it failed to meet its primary endpoint in a mid-stage clinical trial.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
